Dec 12, 2022 / 02:00AM GMT
Julia Wang - BeiGene, Ltd. - CFO & Principal Accounting Officer
Hello, everyone. Welcome to BeiGene's Presentation at the 2022 ASH Conference. My name is Julia Wang, and I'm the Chief Financial Officer of BeiGene. Thank you for joining us today, and we are ready to get the program underway. Before we start, please be reminded that there will be forward-looking statements in our presentation and our business carries certain risks. Some of the risks are discussed in our filings with the SEC, the Hong Kong Stock Exchange and the China Stock Exchange. Please refer to those filings for more details.
With that, we are excited today that we bring together senior executives from BeiGene and the important highly respected external researchers and clinicians to share their insights with us. To take it off, please join me in welcoming John Oyler, our Co-Founder, Chairman and CEO, to give us some opening remarks. John?
John V. Oyler - BeiGene, Ltd. - Co-Founder, Executive Chairman & CEO
Great. Welcome, everyone, for being here and joining us remotely. We're
Beigene Ltd to Discuss Final Results of the ALPINE Trial Q&A Call Transcript
Dec 12, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers